A Phase 1 Study of Single Agent Pexidartinib in Asian Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Pexidartinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 03 Oct 2017 Planned End Date changed from 1 Dec 2020 to 1 Aug 2020.
- 05 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.